Congenital toxoplasmosis

American Family Physician

Volumn 67, Issue 10, 2003, Pages 2131-2138+2145

  Jones, Jeffrey ^a,b   Lopez, Adriana ^a   Wilson, Marianna ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTOZOON ANTIBODY;

ALGORITHM; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CONGENITAL TOXOPLASMOSIS; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS OUTCOME; HUMAN; INFECTION PREVENTION; PREGNANCY; TOXOPLASMA GONDII;

ANIMALS; ANTIBODIES, PROTOZOAN; CATS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL CARE; PRENATAL DIAGNOSIS; SEROLOGIC TESTS; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 0037504166     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001;154:357-65.
2. Alford CA Jr, Stagno S, Reynolds DW. Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med 1974;50:160-81.
3. Kimball AC, Kean BH, Fuchs F. Congenital toxoplasmosis: a prospective study of 4,048 obstetric patients. Am J Obstet Gynecol 1971;111:211-8.
4. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
5. Wilson M, McAuley JM. Toxoplasma. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: American Society for Microbiology, 1999:1374-82.
6. Lynfield R, Guerina NG. Toxoplasmosis. Pediatr Rev 1997;18(3):75-83.
7. Dubey JP. Toxoplasmosis. J Am Vet Med Assoc 1994;205:1593-8.
8. Buzby JC, Roberts T. ERS updates U.S. foodborne disease costs for seven pathogens. FoodReview 1996;19(3):20-5.
9. Roghmann MC, Faulkner CT, Lefkowitz A, Patton S, Zimmerman J, Morris JG Jr. Decreased seroprevalence for Toxoplasma gondii in Seventh Day Adventists in Maryland. Am J Trop Med Hyg 1999;60:790-2.
10. Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia: Saunders, 2001:205-346.
11. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999;353:1829-33.
12. Baril L, Ancelle T, Goulet V, Thulliez P, Tirard-Fleury V, Carme B. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand J Infect Dis 1999;31:305-9.
13. Kapperud G, Jenum PA, Stray-Pedersen B, Melby KK, Eskild A, Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am J Epidemiol 1996;144:405-12.
14. Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000;321:142-7.
15. Weigel RM, Dubey JP, Dyer D, Siegel AM. Risk factors for infection with Toxoplasma gondii for residents and workers on swine farms in Illinois. Am J Trop Med Hyg 1999;60:793-8.
16. Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 1997;350:173-7.
17. Dubey JP. Duration of immunity to shedding of Toxoplasma gondii oocysts by cats. J Parasitol 1995;81:410-5.
18. ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. (Replaces educational bulletin number 177, February 1993). American College of Obstetricians and Gynecologists.
19. Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997;35:3112-5.
20. Foulon W. Congenital toxoplasmosis: is screening desirable? Scand J Infect Dis Suppl 1992;84:11-7.
21. Bader TJ, Macones GA, Asch DA. Prenatal screening for toxoplasmosis. Obstet Gynecol 1997;90:457-64.
22. Montoya JG, Remington JS. Toxoplasma gondii. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:2858-88.
23. Jenum PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondi infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997;35:1972-7.
24. Liesenfeld O, Montoya JG, Tathineni NJ, Davis M, Brown BW Jr, Cobb KL, et al. Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am J Obstet Gynecol 2001;184:140-5.
25. Foulon W, Pinon JM, Stray-Pedersen B, Pollak A, Lappalainen M, Decoster A, et al: Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol 1999;181:843-7.
26. Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med 1994;331:695-9.
27. Daffos F, Forestier F, Capella-Pavlovsky M, Thulliez P, Aufrant C, Valenti D, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 1988;318:271-5.
28. Drugs for parasitic diseases. Medical Letter. Retrieved February 5, 2003, from www.medletter.com/freedocs/parasitic.pdf.
29. Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. BMJ 1999;318:1511-4.
30. Gilbert R, Dunn D, Wallon M, Hayde M, Prusa A, Lebech M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001;127:113-20.
31. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999;180(2 pt 1):410-5.
32. Carter AO, Frank JW. Congenital toxoplasmosis: epidemiologic features and control. CMAJ 1986;135:618-23.
33. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980;66:767-74.
34. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72.
35. Preventing congenital toxoplasmosis. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2000;49(RR-2):57-75.
36. Carter AO, Gelmon SB, Wells GA, Toepell AP. The effectiveness of a prenatal education programme for the prevention of congenital toxoplasmosis. Epidemiol Infect 1989;103:539-45.
37. Foulon W, Naessens A, Lauwers S, De Meuter F, Amy JJ. Impact of primary prevention on the incidence of toxoplasmosis during pregnancy. Obstet Gynecol 1988;72(3 pt 1):363-6.